IBS pharmacotherapy has expanded beyond the antispasmodics and antidiarrheals of traditional management toward targeted therapies addressing IBS pathophysiology including gut motility, visceral hypersensitivity, and gut microbiome dysbiosis, with the Gastrointestinal Therapeutics Market reflecting the market for linaclotide, lubiprostone, tenapanor, rifaximin, and alosetron that collectively...